Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 498-503

  Fleishaker, Joseph C ^a   Sisson, Theresa A ^b   Carel, Barbara J ^b   Azie, Nkechi E ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; SEROTONIN 1B AGONIST; VERAPAMIL;

ADULT; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; MIGRAINE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034040497     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106292     Document Type: Article

References (16)

1. 1. Ferrari MD. Migraine. Lancet 1998;351:1043-51.
2. 2. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M, Whalley ET. Serotonin and migraine. Ann NY Acad Sci 1990;600:587-98.
3. 3. Cabarrocas X, Salvà M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [abstract]. Cephalalgia 1997;17:421.
4. 4. Salvà M, Palacios JM, Martinez-Tobed A. Metabolism of the novel anti-migraine compound almotriptan (LAS 31416) in humans. Abstract presented at the Sixth International Society for the Study of Xenobiotics Meeting, June 30-July 3, 1997.
5. 5. McTavish D, Sorkin EM. Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1989;38:19-76.
6. 6. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997;17:73-80.
7. 7. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-72.
8. 8. Christians U, Schmidt G, Bader A, Lampen A, Schottmann R, Linck A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. Br J Clin Pharmacol 1996;41:187-90.
9. 9. Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJA, Burke MT, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent, in humans. Br J Clin Pharmacol [in press].
10. 10. Trilogy Consulting Corporation Clinical Pharmacokinetics Analysis Program, version 1 user's manual. Kalamazoo (MI): Trilogy Consulting Corporation; 1996.
11. 11. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
12. 12. SAS Institute. SAS/STAT user's guide, version 6. Cary (NC): SAS Institute; 1990.
13. 13. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
14. 14. Döppenschmitt S, Spahn-Langguth H, Regårdh CG, Langguth P. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm Res 1998;15:1001-6.
15. 15. Palacios JM, Rabasseda X, Castañer J. Almotriptan. Drugs Future 1999;24:367-74.
16. 16. Van Hecken Am, Depré M, de Schepper PJ, Fowler PA, Lacey LF, Durham JM. Lack of effect of flunarizine on the pharmacokinetics and pharmacodynamics of sumatriptan in healthy volunteers. Br J Clin Pharmacol 1992;34:82-4.